{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:17:42Z","timestamp":1762899462977,"version":"3.40.5"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T00:00:00Z","timestamp":1512432000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Reactive immunization with a single-dose cholera vaccine that could rapidly (within days) protect immunologically naive individuals during virgin soil epidemics, when cholera reaches immunologically naive populations that have not experienced cholera for decades, would facilitate cholera control. One dose of attenuated\n            <jats:named-content content-type=\"genus-species\">Vibrio cholerae<\/jats:named-content>\n            O1 classical Inaba vaccine CVD 103-HgR (Vaxchora) containing \u22652 \u00d7 10\n            <jats:sup>8<\/jats:sup>\n            CFU induces vibriocidal antibody seroconversion (a correlate of protection) in &gt;90% of U.S. adults. A previous CVD 103-HgR commercial formulation required \u22652 \u00d7 10\n            <jats:sup>9<\/jats:sup>\n            CFU to elicit high levels of seroconversion in populations in developing countries. We compared the vibriocidal responses of Malians (individuals 18 to 45 years old) randomized to ingest a single \u22652 \u00d7 10\n            <jats:sup>8<\/jats:sup>\n            -CFU standard dose (\n            <jats:italic>n<\/jats:italic>\n            = 50) or a \u22652 \u00d7 10\n            <jats:sup>9<\/jats:sup>\n            -CFU high dose (\n            <jats:italic>n<\/jats:italic>\n            = 50) of PaxVax CVD 103-HgR with buffer or two doses (\n            <jats:italic>n<\/jats:italic>\n            = 50) of Shanchol inactivated cholera vaccine (the immunologic comparator). To maintain blinding, participants were dosed twice 2 weeks apart; CVD 103-HgR recipients ingested placebo 2 weeks before or after ingesting vaccine. Seroconversion (a \u22654-fold vibriocidal titer rise) between the baseline and 14 days after CVD 103-HgR ingestion and following the first and second doses of Shanchol were the main outcomes measured. By day 14 postvaccination, the rates of seroconversion after ingestion of a single standard dose and a high dose of CVD 103-HgR were 71.7% (33\/46 participants) and 83.3% (40\/48 participants), respectively. The rate of seroconversion following the first dose of Shanchol, 56.0% (28\/50 participants), was significantly lower than that following the high dose of CVD 103-HgR (\n            <jats:italic>P<\/jats:italic>\n            = 0.003). The vibriocidal geometric mean titer (GMT) of the high dose of CVD 103-HgR exceeded the GMT of the standard dose at day 14 (214 versus 95,\n            <jats:italic>P<\/jats:italic>\n            = 0.045) and was \u223c2-fold higher than the GMT on day 7 and day 14 following the first Shanchol dose (\n            <jats:italic>P<\/jats:italic>\n            &gt; 0.05). High-dose CVD 103-HgR is recommended for accelerated evaluation in developing countries to assess its efficacy and practicality in field situations. (This study has been registered at ClinicalTrials.gov under registration no. NCT02145377.)\n          <\/jats:p>","DOI":"10.1128\/cvi.00265-17","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T01:00:23Z","timestamp":1507770023000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":6,"title":["Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator"],"prefix":"10.1128","volume":"24","author":[{"given":"Samba O.","family":"Sow","sequence":"first","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"},{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagritos D.","family":"Tapia","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"},{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7741-5536","authenticated-orcid":false,"given":"Wilbur H.","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadima C.","family":"Haidara","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen L.","family":"Kotloff","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Blackwelder","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"Institute for Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awa","family":"Traor\u00e9","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boubou","family":"Tamboura","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moussa","family":"Doumbia","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatoumata","family":"Diallo","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flanon","family":"Coulibaly","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Onwuchekwa","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoudou","family":"Kodio","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins, Bamako, Mali"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon M.","family":"Tennant","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mardi","family":"Reymann","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana F.","family":"Lam","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"},{"name":"Institute for Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Gurwith","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lock","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Yonker","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Smith","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub K.","family":"Simon","sequence":"additional","affiliation":[{"name":"PaxVax, Inc., Redwood City, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron M.","family":"Levine","sequence":"additional","affiliation":[{"name":"Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92432-F"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1204927"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.070"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90120-1"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1993.tb06355.x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1291348"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.10.4430-4432.1992"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.12.6341-6345.1999"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw145"},{"key":"e_1_3_3_11_2","first-page":"777","article-title":"The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients","volume":"38","author":"Mosley WH","year":"1968","unstructured":"Mosley WH AhmadS BenensonAS AhmedA. 1968. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ38:777\u2013785.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.2.236"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00098-17"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000221"},{"key":"e_1_3_3_15_2","first-page":"327","article-title":"A serological survey for cholera antibodies in rural east Pakistan. I. The distribution of antibody in the control population of a cholera vaccine field-trial area and the relation of antibody titer to the pattern of endemic cholera","volume":"38","author":"Mosley WH","year":"1968","unstructured":"Mosley WH BenensonAS BaruiR. 1968. A serological survey for cholera antibodies in rural east Pakistan. I. The distribution of antibody in the control population of a cholera vaccine field-trial area and the relation of antibody titer to the pattern of endemic cholera. Bull World Health Organ38:327\u2013334.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2016.07.003"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-8-129"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92231-4"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.9.3994-3997.1993"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.6.1042"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10629360600810434"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.5.1169"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.2.707-709.1995"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199907000-00011"},{"key":"e_1_3_3_25_2","first-page":"187","article-title":"Report of the 1966-67 cholera vaccine field trial in rural east Pakistan. 2. Results of the serological surveys in the study population\u2014the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae","volume":"40","author":"Mosley WH","year":"1969","unstructured":"Mosley WH McCormackWM AhmedA ChowdhuryAK BaruiRK. 1969. Report of the 1966-67 cholera vaccine field trial in rural east Pakistan. 2. Results of the serological surveys in the study population\u2014the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ40:187\u2013197.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02021-16"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.075"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.073"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61140-0"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312680"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510330"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.108"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.09.008"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00006-2"},{"key":"e_1_3_3_35_2","first-page":"214","article-title":"Tolerancia, immunogenicidad, excresi\u00f3n y transmisi\u00f3n de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en ni\u00f1os Chilenos de 24 a 59 meses","volume":"53","author":"Lagos R","year":"1996","unstructured":"Lagos R LosonskyG AbregoP San MartinO PradoV WassermanS LevineMM. 1996. Tolerancia, immunogenicidad, excresi\u00f3n y transmisi\u00f3n de la vacuna anti-colera oral viva-atenuada, CVD 103-HgR, estudio pareado de doble ciego en ni\u00f1os Chilenos de 24 a 59 meses. Bol Hosp Infant Mex53:214\u2013220.","journal-title":"Bol Hosp Infant Mex"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/315051"},{"key":"e_1_3_3_37_2","first-page":"63","article-title":"A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali","volume":"76","author":"Perry RT","year":"1998","unstructured":"Perry RT PloweCV Koumar\u00e9B KotloffKL LosonskyGA WassermanSS LevineMM. 1998. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali. Bull World Health Organ76:63\u201371.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.073"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.02.003"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.03.009"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60844-2"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.3.328"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/145.4.465"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00265-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00265-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:43:22Z","timestamp":1627573402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00265-17"}},"subtitle":[],"editor":[{"given":"Drusilla L.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1128\/CVI.00265-17"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00265-17","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"type":"print","value":"1556-6811"},{"type":"electronic","value":"1556-679X"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"2017-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}